Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.42 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9183600 | 1.00 | TAAR1 (0.47) | TAAR1SLC6A2TDP1TNNC1S1PR1 | |
| SCHEMBL21058237 | 0.87 | TAAR1 (0.54) | TAAR1SLC6A2TDP1GRM2GRM3 | |
| SCHEMBL7716311 | 0.87 | MAOA (0.47) | TNNC1S1PR1S1PR3SGPL1S1PR4 | |
| SCHEMBL4809858 | 0.84 | LTA4H (0.57) | SLC6A2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL4809864 | 0.84 | LTA4H (0.57) | SLC6A2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL29802236 | 0.84 | LTA4H (0.57) | SLC6A2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL3510090 | 0.83 | S1PR1 (0.55) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL3509446 | 0.83 | S1PR1 (0.55) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL13614227 | 0.82 | CYP1A2 (0.47) | TAAR1TNNC1S1PR1S1PR3SGPL1 | |
| SCHEMBL6303133 | 0.82 | TNNC1 (0.40) | TNNC1S1PR1S1PR3SGPL1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| US-6372800-B1 | IMMUNOSUPPRESSIVE EFFECT AND IS USEFUL AS AN INHIBITOR FOR THE REJECTION REACTION OCCURRING IN ORGAN OR BONE MARROW TRANSPLANTATION, AND AS A PREVENTIVE OR REMEDY FOR ARTICULAR RHEUMATISM, ATOPIC ECZEMA (DERMATITIS), BEHCET'S DISEASE, | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-0778263-B1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | WELFIDE CORP (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6187821-B1 | SUCH AS 2-AMINO-2-(3-(4-HEPTYLPHENYL)PROPYL)BUTANE-1,4-DIOL; IMMUNOSUPPRESSANT; ADMINISTERING TO TREAT OR PREVENT AUTOIMMUNE DISEASES AND ALLERGIES | WELFIDE CORPORATION (JP) | 2001-02-13 | — | — | US | disclosed |
| US-5948820-A | IMMUNOSUPPRESSANT; PREVENT REJECTION OF ORGAN TRANSPLANT;AUTOIMMUNE DISEASES; MULTIPLE SCLEROSIS; LUPUS; ANTIALLERGENS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0778263-A1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | TAAR1 4546/4885SLC6A2 3130/4885TDP1 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.